myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
Conditions
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 65 Years
Inclusion criteria
Inclusion criteria: Having the consent and willingness to participate in the study Age range from 35 to 65 years Passing 6 to 8 weeks after the first heart attack BMI< 30 Kg/m2
Exclusion criteria
Exclusion criteria: Smoking, alcohol consumption or narcotic use Taking vitamin, antioxidant or omega-3 supplements in the last 3 months Taking non-steroidal anti-inflammatory drugs over the past 3 months Suffering or having a history of chronic inflammation, kidney, liver and thyroid disease The occurrence of any problem or sensitivity at any time during the study Non-compliance with treatment (less than 80% or less than 48 days) Changes in physical activity, diet, or change in the type and dosage of the drug during the study and the occurrence of acute illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor necrosis factor alpha (TNF-a). Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of TNF-a in serum is with ELISA method.;High-sensitive C-reactive protein (hs-CRP). Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of hs-CRP in serum with Immunoturbidimetry method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Interleukin 6 (IL-6). Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of IL-6 in serum with ELISA method.;Total Antioxidant Capacity (TAC). Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: The level of TAC in serum with ELISA method.;Quality of life. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Myocardial infarction dimensional assessment scale (MIDAS) questionnaire.;Systolic blood pressure. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: sphygmomanometer (mmHg).;Diastolic blood pressure. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: sphygmomanometer (mmHg).;Body Mass Index (BMI). Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: body weight in kilograms divided by the square of the body height in meters (kg/m2).;Waist circumference. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Midpoint between the lower margin of the last palpable rib and the top of the iliac crest.;Body fat percentage. Timepoint: At the baseline and after 8 weeks of intervention. Method of measurement: Body composition monitor scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Vafa
Iran University of Medical Sciences
Outcome results
None listed